New Ultra-High-Throughput PCR Testing System for SARS-CoV-2 Detection Can Test up to 150,000 Patient Samples per Day

A new ultra-high-throughput PCR testing system for SARS-CoV-2 detection can test up to 150,000 patient samples per day.

The proven molecular genomics testing platform with unmatched capacity that has been developed by LGC, Biosearch Technologies (Hertfordshire, UK) is expected to redefine large-scale COVID-19 testing. For labs ready to scale to support mass testing, the company is offering the ultra-high-throughput (uHTP) end-point PCR testing system for SARS-CoV-2 detection.

The Biosearch Technologies workflow combines the Nexar industrial scale, automated end-point PCR testing platform with our robust, high-quality testing reagent components. UgenTec’s FastFinder software seamlessly integrates with the company’s instrumentation to provide full traceability of the sample down to individual wells on the Array Tape consumable, which allows the user to easily pull up a sample’s status. Biosearch Technologies’ SARS-CoV-2 testing workflow can expand testing capacity to as many as 150,000 samples per day with minimal need for additional staff, instrumentation, or lab space.

Biosearch Technologies' SARS-CoV-2 testing system is good for screening symptomatic and asymptomatic individuals. It is compatible with anterior nares specimens self-collected in a non-medical setting or by a healthcare professional within a healthcare setting. The system features an easy dry swab collection device that is safe for handling, better for shipping, and automation-friendly. Biosearch Technologies’ SARS-CoV-2 testing workflow features an extraction-free process without compromising sensitivity of a 250 cp/swab limit of detection (LoD).

Related Links:
LGC, Biosearch Technologies